Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia
The Prostate May 06, 2020
Popovics P, Awadallah WN, Kohrt SE, et al. - Researchers assessed if osteopontin (OPN), a proinflammatory and profibrotic molecule, is elevated in symptomatic benign prostatic hyperplasia (BPH) and tested if prostate epithelial and stromal cells secrete OPN in response to proinflammatory stimuli and identified downstream targets of OPN in prostate stromal cells. This study conducted immunohistochemistry on prostate sections collected from the transition zone of patients who underwent surgery (Holmium laser enucleation of the prostate) to relieve LUTS (surgical BPH, S‐BPH) or patients who had undergone radical prostatectomy to remove low‐grade prostate cancer (incidental BPH, I‐BPH). Compared to men with I‐BPH, it was found that OPN is more abundant in prostates of men with S‐BPH . Proinflammatory cytokines stimulated OPN secretion, and OPN acts directly on stromal cells to drive the synthesis of proinflammatory mRNAs. The data showed that pharmacological manipulation of prostatic OPN may have the potential to decrease LUTS by inhibiting both inflammatory and fibrotic pathways.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins